Image-Guided Peri-Tumoral Radiofrequency Hyperthermia-Enhanced Direct Chemo-Destruction of Hepatic Tumor Margins

Minjiang Chen1,2†, Feng Zhang1†, Jingjing Song1,2, Qiaoyou Weng1,2, Peicheng Li1, Qiang Li1, Kun Qian1, Hongxiu Ji1,3, Sean Pietrini1, Jiansong Ji2* and Xiaoming Yang1*

1 Image-Guided Bio-Molecular Interventions Research & Division of Interventional Radiology, Department of Radiology, University of Washington School of Medicine, Seattle, WA, United States, 2 Key Laboratory of Imaging Diagnosis and Minimally Invasive Interventional Research of Zhejiang Province, Department of Radiology, Zhejiang University Lishui Hospital, Lishui, China, 3 Department of Pathology, Overlake Medical Center and Incyte Diagnostics, Bellevue, WA, United States

Purpose: To validate the feasibility of using peri-tumoral radiofrequency hyperthermia (RFH)-enhanced chemotherapy to obliterate hepatic tumor margins.

Method and Materials: This study included in vitro experiments with VX2 tumor cells and in vivo validation experiments using rabbit models of liver VX2 tumors. Both in vitro and in vivo experiments received different treatments in four groups (n=6/group): (i) RFH-enhanced chemotherapy consisting of peri-tumoral injection of doxorubicin plus RFH at 42°C; (ii) RFH alone; (iii) doxorubicin alone; and (iv) saline. Therapeutic effect on cells was evaluated using different laboratory examinations. For in vivo experiments, orthotopic hepatic VX2 tumors in 24 rabbits were treated by using a multipolar radiofrequency ablation electrode, enabling simultaneous delivery of both doxorubicin and RFH within the tumor margins. Ultrasound imaging was used to follow tumor growth overtime, correlated with subsequent histopathological analysis.

Results: In in vitro experiments, MTS assay demonstrated the lowest cell proliferation, and apoptosis analysis showed the highest apoptotic index with RFH-enhanced chemotherapy, compared with the other three groups (p<0.01). In in vivo experiments, ultrasound imaging detected the smallest relative tumor volume with RFH-enhanced chemotherapy (p<0.01). The TUNEL assay further confirmed the significantly increased apoptotic index and decreased cell proliferation in the RFH-enhanced therapy group (p<0.01).

Conclusion: This study demonstrates that peri-tumoral RFH can specifically enhance the destruction of tumor margins in combination with peri-tumoral injection of a chemotherapeutic agent. This new interventional oncology technique may address the critical clinical problem of frequent marginal tumor recurrence/persistence following thermal ablation of large (>3 cm) hepatic cancers.

Keywords: radiofrequency hyperthermia, liver malignancies, chemotherapy, image-guided interventional oncology, peri-tumoral injection
INTRODUCTION

Advanced ablative and embolic techniques in interventional oncology have become important tools in the multidisciplinary approach to manage patients with primary and secondary liver malignancies. Image-guided percutaneous ablation techniques include ethanol ablation (EA), radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, and irreversible electrophoresis (IRE). Each technique has its own implicit advantages and disadvantages. EA is currently uncommon in clinical practice due to its high local tumor progression rate, which usually requires multiple treatment sessions (1, 2). Cryoablation of medium-to-large tumors often results in serious complications (particularly in the case of liver cirrhosis) and tumor recurrences (3, 4). To date, there is no sufficient data to support the superiority of IRE over the other ablation techniques (5, 6). Embolic (non-ablative) interventional techniques primarily include chemoembolization and radioembolization. The primary limitation of chemoembolization is the frequent development of tumor resistance to chemotherapy (7), while radioembolization is often technically complex (requiring two separate angiographic procedures for vascular mapping/lung-shunt fraction calculations and treatment infusion) with high cost and uncertain future for reimbursement by major insurance payers (8).

Both RFA and MWA are thermal ablation techniques. RFA—the older and more established technique—is universally adapted, well studied, and recommended by different organizations around the world. The use of MWA has been increasing in recent years due to the theoretical advantages of decreased heat sink effect and creation of wider and better regulated ablation zones compared with RFA (9, 10). However, due to the limitations in the achievable size and distribution of the ablation zone, thermal ablation—and indeed all ablative techniques—are most suitable for treating only small tumors (<3 cm) (11, 12). In treating medium (3–5 cm) to large (5–7 cm) lesions, thermal ablation generally results in positive tumor margins (13, 14). The challenge of adequately ablating larger tumors is even greater in light of the fact that an effective and safe ablative zone must extend 1 cm beyond the tumor margin (so-called the surgical margin) using the current thermal ablation technology (15, 16). Several factors contribute to this phenomenon: 1) RFA thermal energy can be carried away by the neighboring vasculature at the tumor periphery (the so-called heat-sink effect); 2) intentional avoidance of MWA’s rapid over-heating by the operator in order to protect adjacent critical structures (such as vasculature, bile ducts, the gastrointestinal tract, and diaphragm); 3) infiltrative growth patterns of malignant tumors involving the formation of micro-satellite lesions or micro-venous tumor emboli beyond the surgical margin of ablated tumors; and 4) off-center positioning of the ablation electrode due to limited access windows (17, 18).

Several combination adjuvant and neoadjuvant approaches have been tested to overcome the above limitations (19). One example is to perform bland embolization or chemoembolization prior to RFA, with the intent of reducing downstream hepatic arterial blood flow and diminishing the “heat-sink” effect (20). However, this combination requires two consecutive treatment sessions, exposing patients to the risks of both procedures with increasing the possibility of multifocal tumor recurrence/progression through repeated manipulation (21). Another example of combination therapy is to administer systemic chemotherapy in addition to RFA. This involves the limitations of systemic chemotherapy, including possible sub-therapeutic drug dose reaching the tumor site, toxicity to other vital organs, and frequent development of chemoresistance. A few reports describe a combination of RFA with radioembolization using Yttrium-90. This approach is not only expensive and technically cumbersome but also currently un-reimbursable by insurances (22). Thus, to date, there is no ideal imaging-guided interventional technique for efficiently eradicating all tumor cells in medium- and large-sized malignant tumors.

To address this critical clinical problem, we propose percutaneously deliver anti-tumor agents to the tumor periphery simultaneously during image-guided ablation sessions. Recently, studies from our group and others also have confirmed that RFA-mediated hyperthermia (RFH) can greatly enhance local gene/chemo/oncolytic therapies of various malignancies, including hepatic tumors (23–26). The groundwork laid by these studies has allowed us to develop an “one-stop shop” interventional technique for which medium-to-large liver tumors can be treated simultaneously with both site-directed chemotherapy and RFA (Figure 1).

MATERIALS AND METHODS

Study Design

This study included two components: (a) in vitro experiments to prove the principle of the new concept, “RFH enhancement of the tumor-killing effect of chemotherapeutic agents” on VX2 tumor cells; and (b) in vivo experiments to validate the feasibility of this new interventional oncologic technique, “Imaging-guided RFH-enhanced direct chemo-destruction of tumor margin tissues”, in rabbit models with orthotopic VX2 liver tumors using a multi-modal perfusion-thermal RFA electrode.

In Vitro Experiments

RFH-Enhanced Killing Effect of Chemotherapeutic on VX2 Tumor Cells

VX2 tumor cells (IDAC, Tohoku University, Japan) were seeded (8 × 10⁴ per well) in four chamber cell culture plates (Thermo Fisher Scientific, Rochester, NH). RFH was performed by attaching a custom-made 0.022-inch radiofrequency heating wire to the bottom of the chamber and connecting it to a radiofrequency generator. A sterilized 1.1-mm fiberoptic
A temperature probe was placed in the bottom of each chamber and connected to a thermometer (PhotonControl, Burnaby, British Columbia, Canada) for real-time monitoring of the temperatures during the RFH.

The cells were divided into four groups (n=6/group), which were treated by (a) combination therapy consisting of doxorubicin (Doxo, 13.9 μM) with RFH at 42 ± 1°C for 20 min; (b) RFH alone; (c) Doxo alone; and (d) phosphate-buffered saline (PBS). The dose of Doxo (Mylan Institutional LLC, Rockford, IL) for cell treatment was determined by its 50% inhibitory concentration (IC50).

**Cell Viability Assay**

Cell viability was evaluated by MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-methoxyphenyl)-2H-tetrazoli] assay (Promega Corporation, Madison, WI), and measured at 490 nm with a microplate reader (VersaMax; Molecular Devices, Sunnyvale, Calif.). Relative cell viability of the four groups was calculated using the equation of A\text{treated} - A\text{blank}/A\text{control} - A\text{blank}, where A is the absorbance of formazan.

Then, cells culture slides were fixed in 4% paraformaldehyde, counterstained with 4',6-diamidino-2-phenylindole (DAPI; Vector Laboratories, Burlingame, Calif.), and then imaged with a fluorescence microscope.

**Apoptosis Measurement**

The percentages of cell apoptosis were quantified by Annexin V/Propidium iodide (PI) dual staining kit (BD Biosciences, San Diego, CA). Samples were analyzed by a FACScan flow cytometer (BD Biosciences). Data were analyzed using the FlowJo software version 10 (FloJo Data Analysis Software, Ashland, Ore).

**In Vivo Experiments**

The experimental protocol was approved by our Institutional Animal Care and Use Committee. Twenty-four female New Zealand white rabbits (2.5–3.5 kg) were used for the in vivo experiments. All experiments involving rabbits were performed under general anesthesia with the inhalation of isoflurane delivered in oxygen at a flow rate of 1 L per minute.
Creation of Liver VX2 Tumors in Rabbits
VX2 tumor cells were implanted into the thigh muscles of donor rabbits. Approximately 2 weeks later, the donor rabbits were euthanized with intravenous injection of overdose pentobarbital at 100 mg/kg body weight. Then, VX2 tumors in the thigh muscle were harvested and were minced into 1 mm³ pieces under sterile conditions.

For the recipient rabbits, under sterilization a 3- to 40-cm incision was made along the midline below the subxiphoid process to expose the left liver lobe (Figure 2). A 1-mm³ minced tissue fragment from the donor VX2 tumor was directly implanted into the subcapsular parenchyma of the left liver lobe, followed by 5-min manual compression of the tumor injection site with a gelatin sponge (Pharmacia & Upjohn Co, Kalamazoo, MI), and the closure of the abdominal incision with layered sutures.

Introtumoral RFA-Induced Hyperthermia to Enhance Peri-Tumoral Chemo-Destruction of VX2 Liver Tumor
The peri-tumoral infusion of Doxo was performed using a multi-modal perfusion-thermal RFA electrode system, which had multipolar prongs enabling simultaneous peri-tumoral delivery of chemotherapeutic agents and thermal ablation (Figure 3). The array sizes of the prongs were adjustable at a range of 1 to 5 cm in diameter. Peri-tumoral sub-lethal RFH (approximately 42°C) was induced by the temperature gradient from the central-tumoral lethal RFH (approximately 80°C). Simultaneously, a chemotherapeutic agent was delivered to the margins of ablated tumors (Figure 3).

Twenty-four rabbits were divided into four treatment groups (n=6/group): (a) combination therapy consisting of peri-tumoral infusion of Doxo (4 mg/kg) plus RFA-induced peri-tumoral RFH (RFA/RFH) at 42 to 44°C for 20 min; (b) RFA/RFH alone; (c) Doxo alone; and (d) saline.

We used a three-step procedure to cover the entire tumor margin. Under ultrasound imaging guidance (Sonosite Inc, Bothel, WA), we first positioned the tip of the multi-modal electrode in the distal portion of the VX2 tumor, then opened the electrode prongs to completely cover the tumor margin. While infusing 4 mg/kg Doxo into the tumor periphery under ultrasound guidance, RFA/RFH was generated at 42°C to 44°C for 20 min and monitored/controlled using the digital panel of the electrode system. Then, the electrode was withdrawn to the central portion of the tumor, and peri-tumoral infusion of Doxo with simultaneous RFA/RFH again for 20 min was again performed. Finally, the proximal portion of the tumor was treated in the same manner (Figure 3).

Post-Treatment Follow-Up
Ultrasound imaging was performed to assess the changes in tumor size at days 0, 7, and 14 after the treatments. The transverse (X), longitudinal (Y), and AP (Z) diameters of the tumors were measured on the ultrasound images. The volume of each tumor was calculated according to the equation: \( V = \frac{X \times Y \times Z \times \pi}{6} \), where \( V \) is tumor volume. Data were presented as relative tumor volume (RTV) by using the following equation: \( RTV = \frac{V_{Dn}}{V_{D0}} \), where \( Dn \) represents days after treatments, \( D0 \) is the day before treatments, and \( Dn \) is the day after the treatments.

Histopathology
Tumor tissues were harvested, fixed in 4% paraformaldehyde solution, and embedded in paraffin. These tumor tissues were cut into 5-mm sections for the following histopathological staining preparations: (a) hematoxylin-eosin (HE) to confirm the formation of liver VX2 tumor; (b) terminal deoxynucleotidyl transferase biotin-dUPT nick end labeling (TUNEL) to determine tumor cell apoptosis; and (c) Ki-67 immunostaining (Abcam, Cambridge, MA) to assess tumor proliferations among four groups. Positive cells were imaged using a microscope (200× amplification; Olympus, Tokyo, Japan), and counted by Image-pro Plus 6.0 software (Media Cybernetics, Silver Spring, MD).

The systemic toxicity of Doxo in different groups was also evaluated by hematoxylin-eosin (H&E) staining, which was performed on the lung, heart, kidney, and spleen.

Statistical Analysis
Statistical software (SPSS, Version 19.0; Chicago, Ill) was used for all data analyses. The non-parametric Mann-Whitney U test was used to compare (i) relative proliferation rates among different cell groups, (ii) tumor volumes, (iii) proliferation rates,
and (iv) apoptotic indexes at different time points among different animal groups with various treatments. Statistical significant was assumed for $P<0.05$.

RESULTS

In Vitro Confirmation: RFH-Enhanced Doxo Killing Effect on VX2 Cells

Confocal microscopy showed the lowest survival of cells in the combination therapy group (RFH+Doxo), compared with the other three treatments groups (Figure 4A). MTS assay further confirmed the significantly lower cell viability with combination therapy compared with Doxo alone, RFH alone, and saline (53.47 ± 2.01% vs 76.23 ± 3.80% vs 92.03 ± 2.24% vs 100%, respectively; $P<0.01$) (Figure 4B). Flow cytometry displayed the highest percentage of apoptotic VX2 cells in the combination therapy group compared with the other three groups (21.8 ± 3.05% vs 12.10 ± 2.34% vs 2.67 ± 0.59% vs 1.43 ± 0.37%, respectively; $P<0.01$) (Figures 4C, D).

In Vivo Validation: RFA/RFH-Enhanced Peri-Tumoral Chemo-Destruction of VX2 Liver Tumors

Ultrasound imaging showed the smallest relative tumor volume in the combination therapy, compared with Doxo alone, RFA/RFH alone, and saline (2.29 ± 0.9 vs 7.23 ± 1.43 vs 11.84 ± 1.45 vs 12.48 ± 2.64, respectively, $P<0.01$) (Figures 5, 6). TUNEL staining demonstrated the significantly higher apoptosis in combination therapy (578.67 ± 173.01 vs 189.33 ± 9.95 vs 29.83 ± 9.95 vs 28.17 ± 8.73, $P<0.01$) (Figure 6). Correspondingly, the cell proliferation analysis by Ki-67 immunostaining further displayed the lower proliferation activity in the combination therapy group, compared with the other three animal groups (230.17 ± 66.08 vs 580.33 ± 82.20 vs 1089.00 ± 134.50 vs 1154.00 ± 131.31, $P<0.01$) (Figure 6).

To further clarify the systemic toxicity of Doxo under this novel treatment mode, H&E staining was performed on the lung, heart, spleen, and kidney (Figure 7). The results of pathology show no abnormal morphological changes and differences among various study groups, suggesting that the local injection
FIGURE 4 | In vitro experiments on therapeutic effect among different treatments groups. (A) Microscopy shows an obvious decrease of viable cells in the RFH + Doxo group, compared to other control groups. (B) MTS assay further confirms that RFH-enhanced chemotherapy results in the lowest cell viability, compared to other control treatments [Doxo+RFH (53.47 ± 2.01%) vs Doxo (76.23 ± 3.80%), RFH (92.03 ± 2.24%), and saline (100%); P<0.05, n=6 per group]. (C) The combination therapy group displays the highest percentage of apoptotic cells. (D) Quantitative analysis of flow cytometry, demonstrating significant increase in apoptotic cells with the combination therapy, compared to other treatments [Doxo+RFH (21.8 ± 3.05%) vs Doxo (12.10 ± 2.34%), RFH (2.67 ± 0.59%), and saline (1.43 ± 0.37%); P<0.05, n=6 per group]. *p < 0.05.

FIGURE 5 | In vivo studies using rabbit models with orthotopic liver VX2 tumors in four groups with different treatments to validate the feasibility of this new interventional oncologic technique. (Left) Ultrasound imaging demonstrates a significant decrease of tumor growth rate at day 14 post-treatment with RFH-enhanced therapy, compared to the other three control treatments [Doxo+RFA/RFH (2.29 ± 0.9) vs Doxo (7.23 ± 1.43), RFA/RFH (11.84 ± 1.45), and saline (12.48 ± 2.64); P<0.05, n=6 per group, Right]. *P < 0.05.
DISCUSSION

Hepatic malignancy (including hepatocellular carcinoma and hepatic metastases) is one of the most common and lethal cancers worldwide (27). Surgical resection is the gold standard curative treatment for liver malignancies. However, only 10% of patients are eligible for surgical resection at the time of tumor diagnosis, due to extent of disease, compromised liver function, and additional comorbidities, including cardiovascular and pulmonary disease (28).

Imaging-guided thermal ablation techniques, primarily including RFA and MWA, have become effective curative locoregional treatment modalities for small-sized hepatic tumors (<3 cm) (29, 30). However, the incidence of tumor recurrence originating at the margin of treated tumor (or within 1 cm of the tumor’s surgical margin) is high when ablating medium (3–5 cm) and large (5–7 cm) hepatic lesions (31–33). In the current study, we attempted to overcome this critical clinical dilemma by developing a new interventional technique using peri-tumoral RFH induced by RFA, which can enhance the destruction of residual tumor cells by a first-line chemotherapeutic agent, doxorubicin (Doxo), at the margin of hepatic tumors.

The results of in vitro experiments in our study demonstrated the enhanced tumor cell killing effect of the combination treatment of RFH plus chemotherapy, manifesting as significantly higher number of apoptotic cells and lower cell viability compared with the other treatment groups. In vivo experiments on rabbit models with orthotopic liver tumors of DOXO did not produce systemic toxicity, and the treatment mode had good biosafety.
further confirmed that the tumor growth was remarkably retarded in the group with the combination therapy compared with the other groups, as revealed by decreased tumor volume, increased apoptosis, and decreased cell proliferation. Our study provides evidence of (a) improved chemotherapeutic efficacy at the tumor margin due to RFA-induced peri-tumoral hyperthermia; and (b) the advantages of the multi-modal perfusion RF ablation electrode system, which has multiple functions of peri-tumoral delivery of high-dose chemotherapeutic agents, generation of RF thermal energy, and real-time temperature monitoring.

This technical development may provide a unique strategy to eliminate the tumor cells at or near the surgical margins of ablated tumors, which are difficult to treat in medium and large-sized tumors by current thermal ablation techniques (34). To ensure full chemotherapeutic coverage of the tumor margins, doxorubicin was infused at the distal, central and proximal portions of the tumor using the same thermal electrode under ultrasound imaging guidance.

We followed up the tumor growth post-treatments only for up to 14 days, due to the consideration that a longer follow-up period would result in tumor size exceeding ten percent of body weight in the animal test subjects, which was not be allowed by our Institutional Animal Care and Use Policy. Since this study primarily focused on the development of our technique, we did not explore the potential mechanisms of RFH-enhanced chemotherapy. We can conjecture that these might involve increasing permeability of cell membranes, increasing cellular metabolism, and accelerated apoptosis of tumor cells by hyperthermia (11, 35, 36).

CONCLUSION

This study has validated the feasibility of using central-tumoral RFA-induced RFH to enhance the effectiveness of peri-tumoral chemo-destruction of tumor margins. We believe that this study may facilitate the development of a new "one-stop-shop" interventional oncology technique, which can enhance the treatment adequacy and address the high rate of recurrence associated with RFA of liver tumors larger than 3 cm.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding authors.
ETHICS STATEMENT
The animal study was reviewed and approved by Institutional Animal Care and Use Committee of University of Washington.

AUTHOR CONTRIBUTIONS
XY and JJ developed the concept and designed the experiments. MC, FZ, JS, and QW performed the experiments and wrote the manuscript. PL, QL, KQ, and HJ collected and analyzed data. SP revised the manuscript. All authors contributed to the article and approved the submitted version.

REFERENCES
1. Weis S, Franke A, Berg T, Mssner J, Fleig WE, Schoppmeyer K. Percutaneous Ethanol Injection or Percutaneous Acetic Acid Injection for Early Hepatocellular Carcinoma. Cochrane Database Syst Rev (2015) 1: CD006745. doi: 10.1002/14651858.CD006745.pub3.
2. Livraghi T, Giorgio A, Marin G, Salmi A, de Sio I, Bolondi L, et al. Hepatocellular Carcinoma and Cirrhosis in 746 Patients: Long-Term Results of Percutaneous Ethanol Injection. Radiology (1995) 197(1):101–8. doi: 10.1148/radiology.197.1.7568806.
3. Nault JC, Sutter O, Ganne-Carrie N, Seror O. Percutaneous Ablation Systems. J Hepatol (2016) 64(3):477–80. doi: 10.1016/j.jhep.2016.01-06-087-x.
4. Liittup PJ, Aoon HD, Adam B, Krycia M, Prus M, Shields A. Percutaneous Cryoablation of Hepatic Tumors: Long-Term Experience of a Large U.S. Series. Abdom Radiol (NY) (2016) 41(4):767–80. doi: 10.1007/s00261-016-0687-x.
5. Niessen C, Thumann S, Beyer L, Pregler B, Kramer J, Lang S, et al. Wiggermann P. Percutaneous Irreversible Electroporation: Long-Term Survival Analysis of 71 Patients With Inoperable Malignant Hepatic Tumors. Sci Rep (2017) 7:43687. doi: 10.1038/srep43687.
6. Rieke J, Jurgens JH, Deschamps F, Tsinkel L, Uhde K, Kosiek O, et al. Irreversible Electroporation (IRE) Fails to Demonstrate Efficacy in a Prospective Multicenter Phase II Trial on Lung Malignancies: The ALICE Trial. Cardiovasc Intervent Radiol (2015) 38(2):401–8. doi: 10.1007/s00270-014-1049-0.
7. Wolf B, Krieg K, Falk C, Breuhahn K, Keppeler H, Biedermann T, et al. Single-Step Multimodal Locoregional Treatment for Unresectable Hepatocellular Carcinoma: An Updated Review. Eur J Cancer (2016) 75:231–40. doi: 10.1016/j.ejca.2016.03-045.
8. Zimmermann A, Grand D, Charpentier KP. Irreversible Electroporation of Hepatocellular Carcinoma: Patient Selection and Perspectives. J Hepatobiliary Pancreat Sci (2017) 24(3):348–58. doi: 10.1002/jhbp.29063.
9. Facciorusso A, Serviddio G, Muscatello I. Local Ablative Treatments for Hepatocellular Carcinoma: An Updated Review. World J Gastrointest Pharmacol Ther (2016) 7(4):477–89. doi: 10.4292/wjgpt.v7i4.477.
10. De Baere T, Tsinkel L, Yevich S, Boige V, Deschamps F, Ducreux M, et al. The Role of Image-Guided Therapy in the Management of Colorectal Cancer Metastatic Disease. Eur J Cancer (2017) 75:231–42. doi: 10.1016/j.ejca.2017.01.010.
11. Chu KF, Dupuy DE. Thermal Ablation of Tumours: Biological Mechanisms and Advances in Therapy. Nat Rev Cancer (2014) 14(3):199–208. doi: 10.1038/nrc3672.
12. Loriaud A, Denys A, Seror O, Violi NV, Digklia A, Duran R, et al. Hepatocellular Carcinoma Abutting Large Vessels: Comparison of Four Percutaneous Ablation Systems. Int J Hyperthermia (2016) 34(8):1154–62. doi: 10.3109/02656736.2018.1440017.
13. Iezzi R, Cesario V, Siciliano L, Campanale M, De Gaetano AM, Siciliano M, et al. Single-Step Multimodal Locoregional Treatment for Unresectable Hepatocellular Carcinoma: Balloon-Occupied Percutaneous Radiofrequency Thermal Ablation (BO-RFA) Plus Transcatheter Arterial Chemoembolization (TACE). Radiol Med (2013) 118(4):555–69. doi: 10.1007/s11547-012-0914-7.
14. Hwang JE, Kim SH, Jin J, Hong JY, Kim MJ, Jung SH, et al. Combination of Percutaneous Radiofrequency Ablation and Systemic Chemotherapy are Effective Treatment Modalities for Metachronous Liver Metastases From Gastric Cancer. Clin Exp Metastasis (2014) 31(1):25–32. doi: 10.1007/s10328-013-9606-5.
15. Beland MD, Wasser EJ, Mayo-Smith WW, Dupuy DE. Primary non-Small Cell Lung Cancer: Review of Frequency, Location, and Time of Recurrence After Radiofrequency Ablation. Radiology (2010) 254(1):301–7. doi: 10.1148/radiol.090090174.
16. Yu MA, Yao L, Zhang L, Peng L, Zhuo L, Zhang Y, et al. Safety and Efficiency of Microwave Ablation for Recurrent and Persistent Secondary Hyperparathyroidism After Parathyroidectomy: A Retrospective Pilot Study. Int J Hyperthermia (2016) 32(2):180–6. doi: 10.3109/02656736.2015.1101788.
17. van Tilborg AA, Scheffer HJ, de Jong MC, Vroomen LG, Nielsen K, van Kuijk C, et al. Mwa Versus RFA for Perivascular and Peribiliary Crlm: A Retrospective Patient- and Lesion-Based Analysis of Two Historical Cohorts. Cardiovasc Intervent Radiol (2016) 39(10):1438–46. doi: 10.1007/s00270-016-1413-3.
18. Bhatia S, Pereira K, Mohan P, Narayanan G, Wangpaisitch M, Savaraj N. Radiofrequency Ablation in Primary Non-Small Cell Lung Cancer: What a Radiologist Needs to Know. Indian J Radiol Imaging (2016) 26(1):81–91. doi: 10.4103/0971-3026.178347.
19. Kadivar F, Soulen MC. Enhancing Ablation: Synergies With Regional and Systemic Therapies. J Vasc Interv Radiol (2010) 21(8 Suppl):S251–6. doi: 10.1016/j.jvir.2010.01.048.
20. Lin ZX, Li GL, Chen J, Chen ZW, Chen YP, Lin SZ. Effect of Heat Sink on the Recurrence of Small Malignant Hepatic Tumors After Radiofrequency Ablation. J Cancer Res Ther (2016) 12(7):153–8. doi: 10.4103/jcrt.JCRT_959_16.
21. Abitabile P, Hartl L, Lange J, Maurer CA. Radiofrequency Ablation Permits an Effective Treatment for Colorectal Liver Metastasis. Eur J Surg Oncol (2007) 33(1):67–71. doi: 10.1016/j.ejso.2006.10.040.
22. Hoffmann RT, Jakobs TF, Kubisch CH, Stemmler HJ, Trumm C, Tatsch K, et al. Radiofrequency Ablation After Selective Internal Radiation Therapy With Yttrium90 Microspheres in Metastatic Liver disease-Is it Feasible? Eur J Radiol (2010) 74(1):199–205. doi: 10.1016/j.ejrad.2009.02.001.
23. Shi Y, Zhang F, Bai Z, Wang J, Qiu L, Li Y, et al. Orthotopic Esophageal Cancers: Intraesophageal Hyperthermia-Enhanced Direct Chemotherapy in Rats. Radiology (2017) 282(1):103–10. doi: 10.1148/radiol.2016122581.
24. Calandri M, Yamashita S, Gazzera C, Fonio P, Veltri A, Bustreo S, et al. Ablation of Colorectal Liver Metastasis: Interaction of Ablation Margins and RAS Mutation Profiling on Local Tumour Progression-Free Survival. Eur Radiol (2018) 28(7):2727–34. doi: 10.1007/s00330-017-5273-2.
25. Ji J, Weng Q, Zhang F, Xiong F, Jin Y, Hui J, et al. Non–Small-Cell Lung Cancer: Feasibility of Intratumoral Radiofrequency Hyperthermia–Enhanced Herpes Simplex Virus Thymidine Kinase Gene Therapy. Radiology (2010) 288(2):612–20. doi: 10.1148/radiol.2010182148.
26. Kumar G, Goldberg SN, Wang Y, Velez E, Gourevitch S, Galun E, et al. Hepatic Radiofrequency Ablation: Markedly Reduced Systemic Effects by Modulating Periablational Inflammation Via Cyclooxygenase-2 Inhibition. Eur Radiol (2017) 27(3):1238–47. doi: 10.1007/s00330-016-4405-4.
27. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global Cancer Statistics. CA Cancer J Clin (2011) 61(2):69–90. doi: 10.3322/caac.20107
28. Park JW, Koh YH, Kim HB, Kim HY, An S, Choi JJ, et al. Phase II Study of Concurrent Transarterial Chemoembolization and Sorafenib in Patients With Unresectable Hepatocellular Carcinoma. J Hepatology (2012) 56(6):1336–42. doi: 10.1016/j.jhep.2012.01.006
29. Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, et al. Small Hepatocellular Carcinoma in Cirrhosis: Randomized Comparison of Radio-Frequency Thermal Ablation Versus Percutaneous Ethanol Injection. Radiology (2003) 228(1):235–40. doi: 10.1148/radiol.2281020718
30. Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, et al. Radiofrequency Ablation for Hepatocellular Carcinoma: 10-Year Outcome and Prognostic Factors. Am J Gastroenterol (2012) 107(4):569–77. doi: 10.1038/ajg.2011.425
31. Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K. Midterm Outcomes in Patients With Intermediate-Sized Hepatocellular Carcinoma. Cancer (2010) 116(23):5452–60. doi: 10.1002/cncr.25314
32. Dong HL, Lee JM, Lee JY, Kim SH, Kim JH, Yoon JH, et al. Non-Hypervascular Hepatobiliary Phase Hypointense Nodules on Gadoteric Acid-Enhanced MRI: Risk of HCC Recurrence After Radiofrequency Ablation. J Hepatology (2015) 62(5):1122–30. doi: 10.1016/j.jhep.2014.12.015
33. Lee YR, Park SY, Kim SU, Jang SK, Lee S, Jang SY, et al. Prediction of Hepatocellular Carcinoma Recurrence After Radiofrequency Ablation Using Liver Stiffness Measurement (Fibroscan). J Hepatology (2016) 64(2):S741–1. doi: 10.2147/OIT.S75077
34. Lewis AR, Padula CA, McKinney JM, Toskich BB. Ablation Plus Transarterial Embolic Therapy for Hepatocellular Carcinoma Larger Than 3 Cm: Science, Evidence, and Future Directions. Semin interventional Radiol (2019) 36 (4):303–9. doi: 10.1055/s-0039-1697641
35. Dunne M, Dou YN, Drake DM, Spence T, Gontijo S, Wells PG, et al. Hyperthermia-Mediated Drug Delivery Induces Biological Effects at the Tumor and Molecular Levels That Improve Cisplatin Efficacy in Triple Negative Breast Cancer. J Controlled Release (2018) 282:35–45. doi: 10.1016/j.jconrel.2018.04.029
36. Quintana C, Cabrera J, Perdomo J, Estévez F, Loro JF, Reiter RJ, et al. Melatonin Enhances Hyperthermia-Induced Apoptotic Cell Death in Human Leukemia Cells. J Pineal Res (2016) 61(3):381–95. doi: 10.1111/jpi.12356

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Chen, Zhang, Song, Weng, Li, Qian, Ji, Pietrini, Ji and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.